Vigeo Therapeutics Presents Preliminary Results from Its Phase 1 Open Label Trial of VT1021 in Patients with Advanced Solid Tumors at ASCO

On May 31, 2019 Vigeo Therapeutics, a clinical-stage biopharmaceutical company developing novel therapeutics to reprogram the tumor immune microenvironment (TIME), reported that preliminary data from its Phase 1 open label trial of VT1021 in patients with advanced solid tumors, will be presented tomorrow, June 1st from 8:00 am to 11:00 am CT at the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) annual meeting being held May 31 – June 4, 2019 in Chicago (Press release, Vigeo Therapeutics, MAY 31, 2019, View Source [SID1234536775]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Vigeo is developing therapies that target the TIME via the induction of thrombospondin-1(Tsp-1) by replicating the biological activity of prosaposin (Psap). Tsp-1 is a naturally occurring potent anti-tumorigenic protein that has been shown to reprogram the TIME and block tumor growth and progression.

"We believe that by reprogramming the TIME, we can significantly improve the outcomes of cancer treatments," said Jing Watnick, Ph.D., M.B.A., chief executive officer of Vigeo. "Emerging clinical data continue to suggest that Vigeo’s VT1021, targeting the tumor microenvironment, is safe and well tolerated and has significant potential in hard-to-treat cancers," she added.

VT1021 in Patients with Advanced Solid Tumors
Dose escalation phase of first in human study with VT1021 is ongoing. Through the first six dose levels tested, VT1021 has been shown to be safe and well tolerated with no serious drug related adverse events. Enrollment for expansion cohorts in specific tumor types is expected to be initiated in the third quarter of 2019.

"The mechanism of action of VT1021 is quite unique," said Gregory Berk MD, chief medical officer of Vigeo. "The molecule has demonstrated an excellent safety profile and PK/PD properties, and is well positioned to be an effective single agent therapy, as well as an ideal partner for standard of care therapies in various oncology indications."


Title: A Phase 1 Study Evaluating the Safety, Pharmacology, and Preliminary Activity of VT1021 in Patients with Advanced Solid Tumors

Date & Time: Saturday June 1, 2019 from 8:00 am – 11:00 am CT

Abstract Session: Developmental Therapeutics and Tumor Biology

Abstract: TPS3158

Location: Board #144a

Presenter: Michael Cieslewicz, PhD, Vice President for Project Management and Operations, Vigeo

About VT1021
Vigeo’s lead molecule, VT1021, is a small peptide agent derived from Psap, that triggers Tsp-1 production, which reprograms the tumor microenvironment and makes it inhospitable for tumor growth to occur. Pre-clinical results have demonstrated that VT1021, when administered systemically, can cause tumor regression in animal models at both the primary and metastatic sites. VT1021 is currently being evaluated in a Phase 1, open label, multicenter trial that assesses the drug’s safety, tolerability, and preliminary anti-tumor efficacy. The trial’s dose escalation phase was launched in late 2017, and the expansion phase will initiate in 3rd quarter of 2019. An interim readout is expected in the second half of 2020.